| Graham T Verlee, MD | |
|
100 Brickhill Ave, South Portland, ME 04106 | |
| (207) 773-1728 | |
| (207) 772-4062 |
| Full Name | Graham T Verlee |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 19 Years |
| Location | 100 Brickhill Ave, South Portland, Maine |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790986495 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | MD18791 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Stephens Memorial Hospital | Norway, ME | Hospital |
| Maine Medical Center | Portland, ME | Hospital |
| Southern Maine Health Care | Biddeford, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Maine Medical Partners | 9335043967 | 789 |
| Mainehealth | 7517860588 | 2067 |
News Archive
Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., a Nevada Corporation, has been sued by Teva Women's Health, Inc., in connection with the filing of Watson's Abbreviated New Drug Application (ANDA) for synthetic conjugated estrogens, A, in the 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg and 1.25 mg tablet strengths. Watson's ANDA is for the generic equivalent of Teva's Cenestin®. The suit was filed on April 23, 2010, in the United States District Court for the District of New Jersey.
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for malaria, HIV/AIDS, hepatitis, tuberculosis and detection, announced today the implementation of a program to accelerate the availability of the world's first Integrated Optical BioSensor (IOBS) platform. The Company is currently reviewing research and manufacturing partnerships to develop simple to replicate bench top versions of the IOBS platform on which single pathogen or multiple pathogen testing assay cartridges can be developed.
Researchers have found the first direct proof that a key protein drives the clogging of arteries in two ways, and that lowering levels of it opens them up, according to study results published in the June edition of the journal Circulation.
In a recent study, researchers developed and validated a nanoimmunoassay (NIA) that analyzes 1,024 samples in parallel on a single microfluidic device the size of a USB stick. They detected anti-SARS-CoV-2 IgG antibodies, achieving a sensitivity of 98% and specificity of 100% based on an analysis of 134 pre-pandemic sera (collected in 2013/2014 and 2018) and 155 sera from reverse transcription-polymerase chain reaction (RT-PCR) positive individuals.
Kaiser Health News staff writer Andrew Villegas asks two experts with differing views whether it was a good idea for the Obama administration to grant one-year waivers to about 30 insurers, employers and union health plans to continue offering what are dubbed "mini-med" insurance plans.
› Verified 1 days ago
| Entity Name | Maine Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598780447 PECOS PAC ID: 9335043967 Enrollment ID: O20040220000847 |
News Archive
Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., a Nevada Corporation, has been sued by Teva Women's Health, Inc., in connection with the filing of Watson's Abbreviated New Drug Application (ANDA) for synthetic conjugated estrogens, A, in the 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg and 1.25 mg tablet strengths. Watson's ANDA is for the generic equivalent of Teva's Cenestin®. The suit was filed on April 23, 2010, in the United States District Court for the District of New Jersey.
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for malaria, HIV/AIDS, hepatitis, tuberculosis and detection, announced today the implementation of a program to accelerate the availability of the world's first Integrated Optical BioSensor (IOBS) platform. The Company is currently reviewing research and manufacturing partnerships to develop simple to replicate bench top versions of the IOBS platform on which single pathogen or multiple pathogen testing assay cartridges can be developed.
Researchers have found the first direct proof that a key protein drives the clogging of arteries in two ways, and that lowering levels of it opens them up, according to study results published in the June edition of the journal Circulation.
In a recent study, researchers developed and validated a nanoimmunoassay (NIA) that analyzes 1,024 samples in parallel on a single microfluidic device the size of a USB stick. They detected anti-SARS-CoV-2 IgG antibodies, achieving a sensitivity of 98% and specificity of 100% based on an analysis of 134 pre-pandemic sera (collected in 2013/2014 and 2018) and 155 sera from reverse transcription-polymerase chain reaction (RT-PCR) positive individuals.
Kaiser Health News staff writer Andrew Villegas asks two experts with differing views whether it was a good idea for the Obama administration to grant one-year waivers to about 30 insurers, employers and union health plans to continue offering what are dubbed "mini-med" insurance plans.
› Verified 1 days ago
| Entity Name | Mainehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790265502 PECOS PAC ID: 7517860588 Enrollment ID: O20040701000166 |
News Archive
Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., a Nevada Corporation, has been sued by Teva Women's Health, Inc., in connection with the filing of Watson's Abbreviated New Drug Application (ANDA) for synthetic conjugated estrogens, A, in the 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg and 1.25 mg tablet strengths. Watson's ANDA is for the generic equivalent of Teva's Cenestin®. The suit was filed on April 23, 2010, in the United States District Court for the District of New Jersey.
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for malaria, HIV/AIDS, hepatitis, tuberculosis and detection, announced today the implementation of a program to accelerate the availability of the world's first Integrated Optical BioSensor (IOBS) platform. The Company is currently reviewing research and manufacturing partnerships to develop simple to replicate bench top versions of the IOBS platform on which single pathogen or multiple pathogen testing assay cartridges can be developed.
Researchers have found the first direct proof that a key protein drives the clogging of arteries in two ways, and that lowering levels of it opens them up, according to study results published in the June edition of the journal Circulation.
In a recent study, researchers developed and validated a nanoimmunoassay (NIA) that analyzes 1,024 samples in parallel on a single microfluidic device the size of a USB stick. They detected anti-SARS-CoV-2 IgG antibodies, achieving a sensitivity of 98% and specificity of 100% based on an analysis of 134 pre-pandemic sera (collected in 2013/2014 and 2018) and 155 sera from reverse transcription-polymerase chain reaction (RT-PCR) positive individuals.
Kaiser Health News staff writer Andrew Villegas asks two experts with differing views whether it was a good idea for the Obama administration to grant one-year waivers to about 30 insurers, employers and union health plans to continue offering what are dubbed "mini-med" insurance plans.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Graham T Verlee, MD 301c Us Route One, Scarborough, ME 04074-9701 Ph: (207) 396-8600 | Graham T Verlee, MD 100 Brickhill Ave, South Portland, ME 04106 Ph: (207) 773-1728 |
News Archive
Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., a Nevada Corporation, has been sued by Teva Women's Health, Inc., in connection with the filing of Watson's Abbreviated New Drug Application (ANDA) for synthetic conjugated estrogens, A, in the 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg and 1.25 mg tablet strengths. Watson's ANDA is for the generic equivalent of Teva's Cenestin®. The suit was filed on April 23, 2010, in the United States District Court for the District of New Jersey.
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for malaria, HIV/AIDS, hepatitis, tuberculosis and detection, announced today the implementation of a program to accelerate the availability of the world's first Integrated Optical BioSensor (IOBS) platform. The Company is currently reviewing research and manufacturing partnerships to develop simple to replicate bench top versions of the IOBS platform on which single pathogen or multiple pathogen testing assay cartridges can be developed.
Researchers have found the first direct proof that a key protein drives the clogging of arteries in two ways, and that lowering levels of it opens them up, according to study results published in the June edition of the journal Circulation.
In a recent study, researchers developed and validated a nanoimmunoassay (NIA) that analyzes 1,024 samples in parallel on a single microfluidic device the size of a USB stick. They detected anti-SARS-CoV-2 IgG antibodies, achieving a sensitivity of 98% and specificity of 100% based on an analysis of 134 pre-pandemic sera (collected in 2013/2014 and 2018) and 155 sera from reverse transcription-polymerase chain reaction (RT-PCR) positive individuals.
Kaiser Health News staff writer Andrew Villegas asks two experts with differing views whether it was a good idea for the Obama administration to grant one-year waivers to about 30 insurers, employers and union health plans to continue offering what are dubbed "mini-med" insurance plans.
› Verified 1 days ago
Stephen Thomas Ryan, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 100 Brickhill Ave, South Portland, ME 04106 Phone: 207-773-1728 Fax: 207-773-8153 | |
Lily C Wang, M.D., PHD Urology Medicare: Medicare Enrolled Practice Location: 100 Brickhill Ave, South Portland, ME 04106 Phone: 207-773-1728 | |
Lisa T Beaule, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 100 Brickhill Ave, South Portland, ME 04106 Phone: 207-773-1728 Fax: 207-772-4062 | |
Dr. Sanchita Bose, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 100 Brickhill Ave, South Portland, ME 04106 Phone: 207-773-1728 | |
Brian M Jumper, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 100 Brickhill Avenue, South Portland, ME 04106 Phone: 207-773-1728 Fax: 207-772-4062 | |
Moritz H Hansen, MD Urology Medicare: Medicare Enrolled Practice Location: 100 Brickhill Avenue, South Portland, ME 04106 Phone: 207-773-1728 Fax: 207-772-4062 | |
Dr. David J Chalmers, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 100 Brickhill Ave, South Portland, ME 04106 Phone: 207-773-1728 |